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The retina is part of the central nervous system and retinal blood vessels are functionally analogous to the cerebral blood vessels ([@B9]). The blood-retinal barrier (BRB) is formed by glial cells, pericytes and endothelial cells ([@B15]). Retinal blood vessels provide abundant energy and oxygen to neuronal and glial cells, while neuronal and glial cells provide growth factors for retinal blood vessels. In order to facilitate this, there is frequent and effective communication between neurons and vessels in the retina. Additionally, the BRB plays an important role in maintaining the function of the retina. An injury to the BRB causes neuroinflammation, which can result in BRB breakdown and neovascularization (NV). There is abundant evidence indicating that retinal NV is often accompanied by neuroinflammation ([@B14]; [@B41], [@B42]), but how exactly neuroinflammation regulates retinal NV remains largely unknown.

Neuroinflammation causes neuronal damage, leading to the development and progression of a variety of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and retinal degeneration ([@B47]), as well as retinal neovascular diseases ([@B45]; [@B42]). This damage triggers a rapid transformation of the retinal microglia into an activated state, switching its function from patrol to shield of the injured site ([@B11]). Activated microglia continue to secrete inflammatory mediators that act on other cells to induce and amplify uncontrolled inflammatory responses. Retinal neurons, such as photoreceptors, have been recently reported to signal for blood vessel growth through inflammatory signals ([@B45]; [@B42]). Pro-inflammatory cytokines and chemokines can cause neuronal apoptosis or death ([@B31]).

Neovascularization is the proliferation of new micro blood vessels in the retina. In clinic, these are called intraretinal microvascular abnormalities, as well as retinal NV when these new blood vessels grow to the surface of the retina ([@B10]). The biggest difference between normal retinal vessels and new blood vessels is that the new blood vessels lack tight junction proteins, which means that the plasma in the NV leaks into the surrounding tissue, such as the vitreous, and causes the degeneration of the vitreous, resulting in vitreous hemorrhage. Furthermore, the subsequent pull on the retina by degraded vitreous may result in retinal detachment, which involves the macula and results in severe vision loss ([@B10]). NV occurs in many ocular diseases, such as retinopathy of prematurity (ROP), age-related macular degeneration (AMD), and diabetic retinopathy (DR). However, the causes of retinal NV may be different among the different types of retinopathy.

Choroidal NV (CNV) is the major cause of vision loss in neovascular AMD. CNV is a process that involves the participation of vascular and extravascular components, such that CNV results in a complex tissue, which is composed of blood vessels, glial cells, myofibroblasts, retinal pigment epithelia, and inflammatory cells ([@B39]). Immune dysregulation and inflammatory processes have been linked with CNV pathogenesis both clinically and experimentally ([@B3]; [@B30]; [@B12]). The release of a series of pro-angiogenic factors may be one of the causes of inflammatory cells triggering angiogenesis ([@B34]). Neutrophil or macrophage depletion was shown to reduce CNV formation ([@B18]; [@B50]). Similarly, macrophage depletion was associated with decreased vascular endothelial growth factor (VEGF) production in laser-induced CNV ([@B18]). The recruitment of blood-derived macrophages appears to be more associated with CNV than resident microglia by bone marrow transplantation experiments ([@B8]). In addition, photoreceptors can control proliferative angiogenesis by modulating photoreceptor inflammatory signals ([@B42]).

Retinopathy of prematurity is a major cause of blindness in children ([@B33]; [@B44]; [@B7]). With advances in neonatal care, smaller and more premature infants who are at high risk for ROP are saved; therefore, increasing the overall incidence of ROP. Currently there is no preventative treatment for ROP. To find new ROP treatments in addition to earlier preventative therapies, understanding the molecular mechanisms of ROP development becomes crucial. Photoreceptors have been reported to play an important role in the ROP pathogenesis ([@B1], [@B2]). Oxygen-induced retinopathy (OIR) is a classical and effective model for studying NV in the ROP ([@B38]; [@B13]). In this model, relative hypoxia leads to an increase in the expression of VEGF in the retina neurons and glial cells ([@B41]). At the same time, hypoxia can also cause neuroinflammation by activating microglia ([@B16]). The continually activated microglia promote inflammation and VEGF expression, and eventually exacerbate NV.

Diabetic retinopathy is a common and complex diabetic complication. Hyperglycemia and dyslipidemia are closely related to the development of DR ([@B20], [@B21]). NV often occurs in the later stages of DR ([@B29]; [@B26]). There are numerous angiogenic molecules that take part in regulated new-vessel formation in DR, including VEGF ([@B43]). The microglia in retinas are activated in animal diabetic models ([@B37]; [@B28]). Recent studies show that inflammatory changes in photoreceptors influence pathological angiogenesis in DR ([@B17]; [@B27]; [@B32]; [@B46]). A dysregulation of communications among neurons including the photoreceptors, vascular cells, and glial cells plays a major role in the pathophysiology of proliferative DR ([@B4]), which is characterized by neovascularization, neuroinflammation and neurodegeneration.

Targeting Neuroinflammation in Neovascular Retinal Diseases {#S2}
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Although NV is the leading cause of blindness in eye diseases, including DR, AMD, and ROP, the detail mechanisms of the pathogenesis of NV are still not well understood ([@B49]). Currently, ablation surgery, angiogenesis inhibitors and growth factor antibody therapy are the primary methods for NV treatment. Angiogenesis inhibitors include ranibizumab, bevacizumab and aflibercept. Bevacizumab is also known as Macugen, Avastin or Lucentis. All of the inhibitors have a similar function -- they mainly inhibit the formation of new retinal blood vessels by inactivating VEGF ([@B6]; [@B20]). However, it is important to note that ablation surgery may cause damage to the retina, and anti-VEGF treatments may inhibit the growth of normal vessels and neurons ([@B19]). It is crucial to find new ways to treat retinal NV.

Because neuroinflammation is associated with retinal NV and promotes retinal NV ([@B21]), it may be possible to target neuroinflammation to treat retinal NV ([@B36]). Recently, there have been attempts to suppress NV through controlling key regulators of inflammatory signals in the eye. Suppressor of cytokine signaling 3 (SOCS3) is an inducible negative feedback regulator of growth factor and inflammation signaling ([@B40]), and plays a critical role in regulating inflammatory responses. SOCS3 is able to prevent pathological angiogenesis, and a conditional loss of SOCS3 in endothelial cells results in increased pathological NV ([@B40]). The expression of SOCS3 is significantly increased in neuronal and glial cells in the OIR mouse model ([@B41]). A conditional knockout of SOCS3 in neuronal and glial cells exacerbates glial cell activation and neuroinflammation while promoting VEGFA expression and retinal NV ([@B41]). In addition, knocking out tumor necrosis factor alpha (TNFα), one of the inflammatory cytokines, appears to be protective in the OIR mouse model ([@B22]). Therefore, targeting the master regulator of cytokine signaling, SOCS3, may provide a new way to reduce neuroinflammation and suppress NV in the eye ([Figure 1](#F1){ref-type="fig"}).
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c-Fos is a proto-oncogene and is also important for many cellular functions. In human photoreceptor cells, c-Fos expression occurs throughout the development process ([@B48]). c-Fos regulates the expression of the rod-specific gene ([@B24]) and apoptosis in photoreceptor ([@B23]; [@B25]; [@B35]). Additionally, c-Fos is strongly related to metabolic demands ([@B42]). In a retinal angiogenesis mouse model of very low-density lipid protein receptor (Vldlr) knockout mice, the expression levels of c-Fos and inflammatory cytokine (TNFα and Interleukin 6) are significantly increased in photoreceptors. Additionally, c-Fos controls retinal NV by modulating the neuroinflammation signals in this model ([@B42]). Therefore, targeting c-Fos may provide another way to reduce neuroinflammation in photoreceptors and prevent the development of NV in retinopathies ([Figure 1](#F1){ref-type="fig"}).

In short, neuroinflammation is closely linked to angiogenesis, and improving the neuroinflammatory mechanism helps to inhibit retinal angiogenesis, while blocking inflammatory signals has also been reported to exacerbate retinal angiogenesis in the CNV model ([@B5]; [@B3]). This happens because inflammation itself has two sides. In the early stages of neuroinflammation, activated glial cells work to clear damaged cells and protect the homeostasis of the retina. Persistent inflammation leads to a loss of control of glial cells, which in turn leads to an attack on their own cells through the secretion of inflammatory factors, exacerbating retinal angiogenesis. Therefore, inhibition of neuroinflammation to treat retinal angiogenesis is still controversial. To seek a better way to treat neuroinflammation, more investigation is needed to explore the detailed relationship between neuroinflammation and angiogenesis.
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